Top

Published in:

01-12-2012 | Epidemiology and Pathophysiology (RA Adler, Section Editor)

HIV Infection and Osteoporosis: Pathophysiology, Diagnosis, and Treatment Options

Authors: Micol S. Rothman, Mary T. Bessesen

Published in: Current Osteoporosis Reports | Issue 4/2012

Abstract

As the population with HIV continues to age, specialists in HIV care are increasingly encountering chronic health conditions, which now include osteoporosis, osteopenia, and fragility fractures. The pathophysiology of the bone effects of HIV infection is complex and includes traditional risk factors for bone loss as well as specific effects due to the virus itself, chronic inflammation, and HAART. Examining risk factors for low bone density and screening of certain patients is suggested, and consideration should be given to treatment for those considered high risk for fracture.

Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med. 2007;146(2):87–95.PubMed

McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791–801. doi:10.1093/infdis/jir188.PubMedCrossRef

Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2010;51(8):963-72. doi:10.1086/656417.

Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165–74. doi:10.1097/QAD.0b013e32801022eb.PubMedCrossRef

Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 2008;22(3):395–402. doi:10.1097/QAD.0b013e3282f423dd.PubMedCrossRef

McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2010;51(8):937-46. doi:10.1086/656412.

Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93(9):3499–504. doi:10.1210/jc.2008-0828.PubMedCrossRef

Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One. 2011;6(2):e17217. doi:10.1371/journal.pone.0017217.PubMedCrossRef

Collin F, Duval X, Le Moing V, Piroth L, Al Kaied F, Massip P, et al. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS. 2009;23(8):1021–4. doi:10.1097/QAD.0b013e3283292195.PubMedCrossRef

10.

Ofotokun I, McIntosh E, Weitzmann MN. HIV: inflammation and bone. Curr HIV AIDS Rep. 2012;9(1):16–25. doi:10.1007/s11904-011-0099-z.CrossRef

11.

Pacifici R. The immune system and bone. Arch Biochem Biophys. 2010;503(1):41–53. doi:10.1016/j.abb.2010.05.027.PubMedCrossRef

12.

Rifas L, Weitzmann MN. A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner. Arthritis Rheum. 2009;60(11):3324–35. doi:10.1002/art.24877.PubMedCrossRef

13.

Vikulina T, Fan X, Yamaguchi M, Roser-Page S, Zayzafoon M, Guidot DM, et al. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A. 2010;107(31):13848–53. doi:10.1073/pnas.1003020107.PubMedCrossRef

14.

Ofotokun I, Weitzmann MN. HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture. Curr Opin Endocrinol Diabetes Obes. 2010;17(6):523–9. doi:10.1097/MED.0b013e32833f48d6.PubMedCrossRef

15.

Brown TT, Ross AC, Storer N, Labbato D, McComsey GA. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antivir Ther. 2011;16(7):1063–72. doi:10.3851/IMP1874.PubMedCrossRef

16.

Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 2009;23(12):1519–29. doi:10.1097/QAD.0b013e32832c1792.PubMedCrossRef

17.

Arora S, Agrawal M, Sun L, Duffoo F, Zaidi M, Iqbal J. HIV and bone loss. Curr Osteoporos Rep. 2010;8(4):219–26. doi:10.1007/s11914-010-0036-x.PubMedCrossRef

18.

Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, Mayer K, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011;6(8):e23688. doi:10.1371/journal.pone.0023688.PubMedCrossRef

19.

Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. N Engl J Med. 2012. doi:10.1056/NEJMoa1110711.

20.

Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther. 2010;15(3):425–9. doi:10.3851/IMP1502.PubMedCrossRef

21.

Gibellini D, Borderi M, de Crignis E, Clo A, Miserocchi A, Viale P, et al. Analysis of the effects of specific protease inhibitors on OPG/RANKL regulation in an osteoblast-like cell line. The new microbiologica. 2010;33(2):109–15.PubMed

22.

Santiago F, Oguma J, Brown AM, Laurence J. Noncanonical Wnt signaling promotes osteoclast differentiation and is facilitated by the human immunodeficiency virus protease inhibitor ritonavir. Biochem Biophys Res Commun. 2012;417(1):223–30. doi:10.1016/j.bbrc.2011.11.089.PubMedCrossRef

23.

Yin MT, Modarresi R, Shane E, Santiago F, Ferris DC, McMahon DJ, et al. Effects of HIV infection and antiretroviral therapy with ritonavir on induction of osteoclast-like cells in postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2011;22(5):1459-68. doi:10.1007/s00198-010-1363-6.

24.

Foca E, Motta D, Borderi M, Gotti D, Albini L, Calabresi A, et al. Prospective evaluation of bone markers, parathormone and 1,25-(OH)(2) vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. BMC Infect Dis. 2012;12:38. doi:10.1186/1471-2334-12-38.PubMedCrossRef

25.

Curran A, Martinez E, Saumoy M, del Rio L, Crespo M, Larrousse M, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS. 2012;26(4):475–81. doi:10.1097/QAD.0b013e32834f3507.PubMedCrossRef

26.

Piso RJ, Rothen M, Rothen JP, Stahl M. Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used. J Acquir Immune Defic Syndr. 2011;56(4):320–4. doi:10.1097/QAI.0b013e31820cf010.PubMedCrossRef

27.

Yin MT, Zhang CA, McMahon DJ, Ferris DC, Irani D, Colon I, et al. Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study. J Clin Endocrinol Metab. 2012;97(2):554–62. doi:10.1210/jc.2011-2197.PubMedCrossRef

28.

Pacifici R. Role of T cells in ovariectomy induced bone loss–revisited. J Bone Miner Res. 2012;27(2):231–9. doi:10.1002/jbmr.1500.

29.

Dickinson SA, Fantry LE. Use of Dual-Energy X-Ray Absorptiometry (DXA) Scans in HIV-Infected Patients. J Int Assoc Phys AIDS Care (Chic). 2012. doi:10.1177/1545109712438751.

30.

Lari M, Parsa N, Marzban M, Shams M, Faramarzi H. Depression, Testosterone Concentration, Sexual Dysfunction and Methadone Use Among Men with Hypogonadism and HIV Infection. AIDS Behav. 2012;on line June 22 2012.

31.

Rochira V, Zirilli L, Orlando G, Santi D, Brigante G, Diazzi C, et al. Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS One. 2011;6(12):e28512. doi:10.1371/journal.pone.0028512.PubMedCrossRef

32.

Pepe J, Isidori AM, Falciano M, Iaiani G, Salotti A, Diacinti D, et al. The Combination Of Frax And Aging Male Symptoms Scale Better Identifies Treated Hiv Males At Risk For Major Fracture. Clin Endocrinol. 2012. doi:10.1111/j.1365-2265.2012.04452.x.

33.

Longenecker CT, Hileman CO, Carman TL, Ross AC, Seydafkan S, Brown TT, et al. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther. 2012;17(4):613–21. doi:10.3851/IMP1983.PubMedCrossRef

34.

Cotter AG, Mallon PW. Therapeutic options for low bone mineral density in HIV-infected subjects. Curr HIV AIDS Rep. 2012;9(2):148–59. doi:10.1007/s11904-012-0117-9.CrossRef

35.

Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab. 2007;92(4):1283–8. doi:10.1210/jc.2006-2216.PubMedCrossRef

36.

Bolland MJ, Grey A, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, et al. Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least Five Years in HIV-Infected Men. J Clin Endocrinol Metab. 2012;97(6):1922–8. doi:10.1210/jc.2012-1424.PubMedCrossRef

37.

Huang J, Meixner L, Fernandez S, McCutchan JA. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS. 2009;23(1):51–7. doi:10.1097/QAD.0b013e32831c8adc.PubMedCrossRef

Title: HIV Infection and Osteoporosis: Pathophysiology, Diagnosis, and Treatment Options
Authors: Micol S. Rothman
Mary T. Bessesen
Publication date: 01-12-2012
Publisher: Current Science Inc.
Published in: Current Osteoporosis Reports / Issue 4/2012
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-012-0125-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

HIV Infection and Osteoporosis: Pathophysiology, Diagnosis, and Treatment Options

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Augmentation of Implant Fixation in Osteoporotic Bone

The Role of Diet in Osteoporosis Prevention and Management

Primary Arthroplasty for Management of Osteoporotic Fractures about the Knee

Which Vitamin D Oral Supplement is Best for Postmenopausal Women?

Brains, Bones, and Aging: Psychotropic Medications and Bone Health Among Older Adults

Idiopathic Hypercalciuria and Bone Health